| Theme |
Obesity Related Digestive Diseases |
| Title |
Present State of Anti-obesity Drugs |
| Author |
Hiroaki Ueno |
Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki |
| Author |
Masamitsu Nakazato |
Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki |
| [ Summary ] |
Obesity is increasing worldwide, including Japan. Obesity related diseases, including diabetes, dyslipidemia and osteoarthritis diminish quality of life and consume medical resources. To reduce excess body weight, anti-obesity drugs, which reduce appetite or lipid absorption from the intestine are being investigated. Although only mazindol can be used in Japan at present, orlistat, lorcaserin and Qsymia can be used in the USA and/or European countries. In addition, other drugs with various mechanisms have been investigated in clinical and basic research. Since some drugs have been withdrawn due to severe side effects, the development and clinical usage of novel anti-obesity drugs with few side effects are looked forward to in Japan. |